Here's why the Starpharma (ASX:SPL) share price is having such a stellar end to the week

The global biopharmaceutical company has great news for ASX investors today.

| More on:
A group of science or medical professionals cheering good news in the lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Starpharma share price is surging 6% in morning trade 
  • The UK regulator has given Starpharma the green light to recommence sales of its VIRALEZE product 
  • VIRALEZE is now in more than 30 countries but is not approved for sale in Australia 

The Starpharma Holdings Limited (ASX: SPL) share price is up 6% following a company announcement to the market this morning.

Starpharma has announced it will relaunch its VIRALEZE antiviral nasal spray in the UK after resolving issues raised by the regulator in June last year. Supply preparations are already underway and the product will be back online and in pharmacies over the next few weeks.

Starpharma share price spikes after regulator's tick of approval

ASX investors have reacted strongly to the news today. The Starpharma share price is heading northwards for a fourth consecutive day. It is currently up 6% on Monday's closing price, trading at 96 cents.

Starpharma paused the sale and promotion of VIRALEZE in the UK after the Medicines and Healthcare Products Regulatory Agency (MHRA) wrote to its UK retail partner, LloydsPharmacy querying promotional claims about VIRALEZE and its impact on COVID-19.

As my Fool colleague Kerry Sun wrote at the time, the correspondence related to "references to SARS-CoV-2 and COVID-19, and the interrelationship between these product claims and its categorisation".

MHRA was not questioning the safety or quality of VIRALEZE. It was querying "allowable promotional claims" under the product's categorisation as a medical device.

On the day of that announcement, the Starpharma share price nosedived by 9.4% to $1.54.

In laboratory studies, VIRALEZE has proven effective in deactivating many respiratory viruses, including influenza and multiple strains of COVID-19.

In its statement today, Starpharma told ASX investors that it had provided MHRA with "extensive technical
information" on VIRALEZE and its anti-viral agent, SPL7013. Overnight, the regulator gave the green light for Starpharma to recommence sales in the UK.

What did management say?

Starpharma CEO Dr Jackie Fairley said:

We are delighted to be relaunching VIRALEZE in the UK. We look forward to making VIRALEZE available to UK consumers again very soon. VIRALEZE is registered in more than 30 countries, and we look forward to rolling the product out into further markets this year.

VIRALEZE is registered as a medical device in the UK and countries across Europe, Asia, and the Middle East. It is not approved for sale in Australia.

Starpharma share price recap

The Starpharma share price hit a 52-week low of 79 cents in the middle of March. ASX investors who picked up Starpharma shares at this price have seen a 21% return on their investment in just over two weeks.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »